Inogen (INGN) Capital Expenditures Growth (3y) (2016 - 2026)
Inogen (INGN) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 9.52% |
| 10 | Inogen | 151.72 Mn | 46.18 Mn | 43.27 Mn | -37.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.50% |
| Mar 31, 2026 | -214.57% |
| Dec 31, 2025 | -178.19% |
| Sep 30, 2025 | 55.71% |
| Jun 30, 2025 | -57.24% |
| Mar 31, 2025 | -40.21% |
| Dec 31, 2024 | -87.64% |
| Sep 30, 2024 | 60.92% |
| Jun 30, 2024 | 265.10% |
| Mar 31, 2024 | 64.35% |
| Dec 31, 2023 | 49.72% |
| Sep 30, 2023 | 38.41% |
| Jun 30, 2023 | -26.32% |
| Mar 31, 2023 | 53.25% |
| Dec 31, 2022 | -26.90% |
| Sep 30, 2022 | -6.64% |
| Jun 30, 2022 | -5.78% |
| Mar 31, 2022 | 13.55% |
| Dec 31, 2021 | -27.27% |
| Sep 30, 2021 | 28.38% |